1. Mitochondrial pH Nanosensors for Metabolic Profiling of Breast Cancer Cell Lines
   Consuelo Ripoll et al, 2020, International Journal of Molecular Sciences CrossRef
2. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
   Kai Chen et al, 2020, Life Sciences CrossRef
3. lncRNA MAGI2‐AS3 overexpression had antitumor effect on Hepatic cancer via miRNA‐23a‐3p/PTEN axis
   Fei Liu et al, 2021, Food Science & Nutrition CrossRef
4. Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53
   Anja Müller et al, 2018, Cell Death & Disease CrossRef
5. KRAS-Mutated Lung Cancer
   Arnab Basu et al, 2019, Targeted Therapies for Lung Cancer CrossRef
6. Molecular classifications of gastric cancers: Novel insights and possible future applications
   Silvio Ken Garattini et al, 2017, World Journal of Gastrointestinal Oncology CrossRef
7. FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells
   Tomeka L. Suber et al, 2018, Respiratory Research CrossRef
8. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers
   Suman Rao et al, 2019, Journal of Biological Chemistry CrossRef
9. Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
   Timothy F. Burns et al, 2020, Journal of Clinical Oncology CrossRef
10. KRAS: Reasons for optimism in lung cancer
    C.R. Lindsay et al, 2018, European Journal of Cancer CrossRef
11. Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS‐mutant human lung cancer cells
    Rebecca M. Peter et al, 2023, Molecular Carcinogenesis CrossRef